| oshpd_id | manufacturer_name | date_reported | ndc_number | drug_product_description | wac_effective_date | wac_increase_amount | wac_after_increase | patent_expiration_date | drug_source_type | unit_sales_volume_in_us | unit_sales_volume_non_public_indicator | cost_increase_factors | cost_increase_factors_non_public_indicator | change_improvement_description | change_improvement_non_public_indicator | acquisition_date | company_acquired_from | acquisition_price | acquisition_price_non_public_indicator | acquisition_price_comment | wac_at_acquisition | wac_year_prior_to_acquisition | year_drug_introduced_to_market | wac_at_intro_to_market | supporting_documents | general_comments |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rx0000082 | Zydus Pharmaceuticals (USA) Inc. | 06/30/2019 | 70710147801 | Fomepizole 1.5g/1.5mL Solution for Injection | 04/25/2019 | 639.06 | 1500.00 | None | Non-innovator Multiple Source Drug | None | 1 | None | 1 | None | 1 | None | None | None | None | None | None | None | None | None | None | This is an AP rated generic drug that was not acquired in the last 5 years. |